Alain Patrick Algazi
University of California, San Francisco · 269 works · 23,026 citations · h-index 53
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF V600 -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli
- Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
- High response rate to PD-1 blockade in desmoplastic melanomas
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Lesions of frontal cortex diminish the auditory mismatch negativity